Burosumab-twza was developed for the treatment of FGF-23 related hypophosphatemia; however, for the purpose of this review, its indication for the treatment of X-linked hypophosphatemia (XLH) in pediatric patients (but including adult treatment) will be discussed. Here, FGF23 is linked to hypophosphatemia.